🟢 HCW Biologics is trading 13% up today after FDA guidance on cancer-study IND next steps

HCW Biologics is trading at $1.73 (+12.95%) after a recent FDA Type B meeting provided guidance on next steps for a first-in-human solid-tumor study.

• The study is for HCW11-018b, the company’s lead T-cell engager candidate.
• Clinical-trial manufacturing is underway, and HCW Biologics continues to target filing its IND in the first half of 2027.